Johns Hopkins ABX Guide
Telbivudine
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis B (HBeAg-negative or -positive) with ongoing viral replication and evidence of transferase elevation or histologically active disease.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 8, 2018
Citation
Smith, Janessa M, and Paul A Pham. "Telbivudine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540539/all/Telbivudine.
Smith JM, Pham PA. Telbivudine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540539/all/Telbivudine. Accessed May 18, 2025.
Smith, J. M., & Pham, P. A. (2018). Telbivudine. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540539/all/Telbivudine
Smith JM, Pham PA. Telbivudine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2025 May 18]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540539/all/Telbivudine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Telbivudine
ID - 540539
A1 - Smith,Janessa,Pharm.D., BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2018/07/08/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540539/all/Telbivudine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
